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OBJECTIVE: Accelerated bone loss that occurs in postmenopausal women has been linked to oxidative stress and
increased free radicals. We propose the use of antioxidants to prevent and reverse postmenopausal
osteoporosis. This study aimed to examine the effects of tocotrienol, a vitamin E analog, on bone loss due to
estrogen deficiency. Our previous study showed that tocotrienol increased the trabecular bone volume and
trabecular number in ovariectomized rats. In the current study, we investigated the effects of tocotrienol
supplementation on various biochemical parameters in a postmenopausal osteoporosis rat model.
MATERIALS AND METHODS: A total of 32 female Wistar rats were randomly divided into four groups. The
baseline group was sacrificed at the start of the study, and another group was sham operated. The remaining
rats were ovariectomized and either given olive oil as a vehicle or treated with tocotrienol at a dose of 60 mg/
kg body weight. After four weeks of treatment, blood was withdrawn for the measurement of interleukin-1
(IL1) and interleukin-6 (IL6) (bone resorbing cytokines), serum osteocalcin (a bone formation marker) and
pyridinoline (a bone resorption marker).
RESULTS: Tocotrienol supplementation in ovariectomized rats significantly reduced the levels of osteocalcin, IL1
and IL6. However, it did not alter the serum pyridinoline level.
CONCLUSION: Tocotrienol prevented osteoporotic bone loss by reducing the high bone turnover rate
associated with estrogen deficiency. Therefore, tocotrienol has the potential to be used as an anti-osteoporotic
agent in postmenopausal women.
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& INTRODUCTION
To maintain its overall health and function, bone
continuously undergoes a regeneration process known as
bone remodeling. The process involves bone resorption by
osteoclasts followed by formation of new bone by osteo-
blasts. Bone resorption and formation are closely coupled
such that the amount of bone destroyed by osteoclasts is
equal to the amount of bone formed by osteoblasts. The
molecular basis of the coupling process in bone remodeling
involves cytokines such as macrophage-colony stimulating
factor (M-CSF), receptor activator of nuclear factor kappa b
ligand (RANKL) and osteoprotegerin (OPG). The binding of
M-CSF and RANKL to their respective surface receptors on
osteoclast precursors enables them to differentiate into
mature multinucleated osteoclast cells. This process is
regulated by osteoprotegerin, which competes with
RANKL to inhibit osteoclast formation (1,2). Meanwhile,
bone resorption causes the release of osteoclast-derived
‘coupling factors’, which are embedded in the bone matrix
by osteoblasts during bone formation. These coupling
factors include growth factors, such as transforming growth
factor beta (TGF-beta), bone morphogenetic proteins and
insulin-like growth factor (IGF), as well as factors produced
and released by osteoclasts, including cardiotropin-1, which
stimulate osteoblast differentiation and bone formation (2).
In postmenopausal osteoporosis, estrogen deficiency
leads to loss of bone, rendering it susceptible to fracture.
The mechanisms for bone loss include RANKL upregula-
tion, which leads to increased osteoclast recruitment and
activation; decreased osteoclast apoptosis; reduced osteo-
protegerin production by osteoblasts, causing an increase in
the RANKL/osteoprotegerin ratio that favors bone resorp-
tion; increased expression of bone-resorbing cytokines, such
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as M-CSF, tumor necrosis factor-a (TNF-a), interleukin-1
and interleukin-6; and a direct effect on osteoclasts via the
inhibition of apoptosis and an increase in the differentiation
of osteoclast precursors into mature osteoclasts (3).
Reactive oxygen species have widely been considered to be
a causal factor in a number of pathological conditions,
including osteoporosis. Studies by Bax et al. (4) and Garrett et
al. (5) reported that osteoclast differentiation and functions
were stimulated by reactive oxygen species. Another study
showed that estrogen deficiency lowered antioxidant
defenses in osteoclasts, resulting in increased osteoclastic
resorption (6). Several of the intracellular signals essential for
osteoclast formation, such as nuclear factor-kappa B (NF-kB),
c-Jun amino-terminal kinase (JNK) and phosphatidylinositol
3-kinase (PI3K) are sensitive to reactive oxygen species (7).
Previous researchers have reported that antioxidant
vitamins can effectively reduce oxidative damage both in
vitro and in vivo (6,8). In the present study, we determined
the effects of vitamin E in the form of tocotrienol on bone
metabolism in ovariectomized rats by analyzing the
biomarkers of bone turnover.
& MATERIALS AND METHODS
Animals
A total of 32 female Wistar rats (three months old),
weighing 160-190 g, were obtained from the Animal House
of the Universiti Kebangsaan Malaysia. The rats were equally
divided at random into four groups with eight rats in each
group. The baseline group was sacrificed at the start of
experiment, and a second group was sham operated. The
remaining rats were ovariectomized and either given olive oil
or treated with tocotrienol at a dose of 60 mg/kg body
weight. The sham rats were also given olive oil. Treatment
commenced two weeks after ovariectomy to allow the rats to
recuperate. Olive oil or tocotrienol was given orally to the rats
using an oral gavage needle six days per week for four weeks.
The rats were housed in standard cages in groups of three
at room temperature with a 12 h light-dark cycle. The
animals were fed with a commercial rat chow diet (Gold
Coin, Klang, Selangor, Malaysia), and tap water was
provided ad libitum. Daily food intakes and weekly body
weights were documented.
Pure tocotrienol
The tocotrienol mixture was prepared by the Palm Oil
Research Institute of Malaysia (PORIM; Malaysian Palm Oil
Board, Kajang, Selangor, Malaysia) and had the following
composition: 37.2% alpha-tocotrienol, 39.1% gamma-tocotrie-
nol and 22.6% delta-tocotrienol. The palm tocotrienol mixture
was diluted in olive oil (Bertolli Classico, Italy) to obtain a
concentration of 60 mg/kg body weight. The dose chosen was
based on our previous study, which showed that at a dose of
60 mg/kg body weight, tocotrienol was able to prevent the
oxidative stress-induced increase in interleukin-1, a bone
resorbing cytokine, in a rat model (9). This dose is equivalent
to 6 mg/kg in humans, or approximately 420 mg for a 70 kg
human, after adjusting for differences in surface area (10).
Specimen collection
The rats were sacrificed by cervical dislocation under
anesthesia with ether. Subsequently, their abdomens were
dissected to expose their hearts for blood sampling via
cardiac puncture. The serum was separated and stored in a
deep freezer at a temperature of -70 C˚.
Serum biochemistry
Serum levels of interleukin-1, interleukin-6, osteocalcin and
pyridinoline were measured at the end of the experiment using
the enzyme immunoassay (EIA) technique. The results
obtained with commercially produced rat enzyme immunoas-
say kits for interleukin-1 (Biosource International, Camarillo,
California, USA), interleukin-6 (BenderMed Systems, Vienna,
Austria), osteocalcin (Biomedical Technologies, Stoughton,
Massachusetts, USA) and pyridinoline (Quidel Corp., San
Diego, California, USA) were analyzed using an enzyme
immunoassay reader (VERSAmax, ELISA Reader, Molecular
Devices LLC, Sunnyvale, California, USA).
Statistical analysis
The results are expressed as the mean¡SEM. Data
analyses were performed using Statistical Package for
Social Sciences software (SPSS, USA). Normality was tested
with the Kolmogorov-Smirnov test. Data that were found to
be normally distributed were subjected to ANOVA followed
by Tukey’s HSD post-hoc analysis. The significance level
was set at p#0.05.
All the protocols used in this study were approved by the
Animal Ethics Committee of the Universiti Kebangsaan
Malaysia (approval number FAR/IMA/23-JULY/075).
& RESULTS
Body weights and food intake
There was no significant difference in the mean body
weights at the start of the experiment. All the rats gained
weight throughout the six-week study. Starting from week
three until the completion of the study, the ovariectomized
rats showed significantly higher body weights compared
with the other rats. Tocotrienol supplementation inhibited
the increase in body weight observed following ovariectomy
(Figure 1). The ovariectomized rats had a higher average
daily food intake compared with the sham and tocotrienol-
treated groups. The daily food intake of rats supplemented
with tocotrienol did not differ significantly from that of the
sham rats (Table 1).
Cytokines
As shown in Figures 2 and 3, ovariectomy caused an
increase in the levels of both interleukin-1 and interleukin-6.
Treatment with tocotrienol successfully prevented this rise
in cytokine levels.
Osteocalcin
The osteocalcin level in tocotrienol-treated rats was
significantly reduced compared with the ovariectomy
control group (Figure 4).
Serum pyridinoline
No significant differences were noted in the levels of
serum pyridinoline in any of the groups of rats (data not
shown).
& DISCUSSION
The purpose of this study was to evaluate the effects of
pure tocotrienol on bone metabolism in ovariectomized
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female rats by measuring biochemical parameters including
the levels of bone-resorbing cytokines (interleukin-1 and
interleukin-6), a bone formation marker (osteocalcin) and a
bone resorption marker (serum pyridinoline). The ovariec-
tomized rat has become a widely accepted model of human
postmenopausal osteoporosis because of the many simila-
rities in their pathophysiological mechanisms (11,12). In
both species, bone loss occurs rapidly after the onset of
estrogen deficiency, resulting in a reduction in bone mineral
density (13). The responses to mechanical influences (e.g.,
exercise) and various treatment modalities are also similar
(14). Although rats are skeletally mature at 10 months old,
the cheaper and more readily available three-month-old rats
are generally used because their bone loss characteristics are
similar to those of the aged rat model. Rats younger than 3
months old are not suitable models for studying bone loss
caused by ovarian deficiency because the normal processes
of bone remodeling and skeletal maturation during growth
may mask the effects of ovariectomy-induced bone loss (15).
In our previous study, we observed no reduction in
trabecular bone volume in ovariectomized rats supplemen-
ted with pure palm tocotrienol. All the structural para-
meters (with the exception of trabecular thickness) were
maintained at the levels of sham rats (16). The results of the
structural histomorphometric analysis suggest that tocotrie-
nols prevent bone resorption by reducing the trabecular
perforation that typically occurs during estrogen deficiency.
We also reported that palm tocotrienols significantly
improved bone dynamic parameters in estrogen-deficient
rats by increasing the mineralizing surface, the mineral
apposition rate and the bone formation rate (17). The effects
of tocotrienol on dynamic parameters indicate that this form
of vitamin E has anabolic properties that result in increased
bone formation. This observation has been confirmed in a
study performed by Shuid et al. (18).
Ovarian hormone deficiency increases bone resorption,
which results in bone mineral loss from the skeleton. Lack
of estrogen disrupts calcium homeostasis, leading to a
negative calcium balance via a combination of decreased
intestinal absorption and increased renal excretion (19). In
addition, reduced estrogen contributes to oxidative stress by
producing excessive free radicals. This process is associated
with low levels of antioxidant enzymes, such as superoxide
dismutase, glutathione peroxidase and glutathione-S-trans-
ferase (20). These enzymes are responsible for metabolizing
free radical molecules to non-radical products. Osteoporotic
patients were found to have low levels of antioxidants (21)
and high levels of free radical species (22). Although toxic to
the bone-forming osteoblasts (23), free radicals activate
osteoclastic bone resorption, which is responsible for bone
loss (5). Bone resorption in postmenopausal osteoporosis
has also been linked to the inflammatory process. Various
studies have demonstrated the connection between osteo-
clasts, M-CSF and inflammatory cytokines such as TNF-a
and interleukins 1, 6 and 7. Estrogen deficiency causes
Figure 1 - Mean body weight. aIndicates a significant difference compared with the ovariectomized group (p,0.05). The data are
presented as the mean¡SEM. Ovx=ovariectomy. Ovx+PTT=ovariectomy treated with pure tocotrienol.
Table 1 - Average food intake.
Sham (n=8) Ovx (n= 8) Ovx+PTT (n= 8)
Average food
intake, g/day
18.75¡0.35a 26.75¡0.67 21.45¡0.56a
aIndicates a significant difference compared with the ovariectomized
group (p,0.05). The data are presented as the mean¡SEM.
Ovx=ovariectomy. Ovx+PTT=ovariectomy treated with pure tocotrienol.
Figure 2 - IL-1 levels in the different groups of rats. * Indicates a
significant difference compared with the ovariectomy (Ovx)
group (p,0.05). Ovx+PTT=Ovariectomy+pure tocotrienol. The
data are presented as the mean¡SEM.
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increased production of inflammatory cytokines, which
stimulate osteoclasts to resorb bone via the binding of
RANKL to its receptor (RANK) (24).
In our current study, ovariectomized rats had elevated
levels of interleukins 1 and 6. The osteocalcin level, which is
a marker of bone formation, was also increased. This is
consistent with previous findings that bone loss in ovar-
iectomy is due to a high bone turnover rate with resorption
exceeding formation (11,25). The increase in the levels of
cytokines and osteocalcin in ovariectomized rats was
prevented by supplementation with tocotrienols. This
finding is in agreement with our earlier studies, in which
tocotrienols were able to reduce the interleukin-1 and
interleukin-6 levels in a free radical-induced osteoporotic
rat model (9).
The lack of a serum pyridinoline response in this study
could be due to the short duration of the study period. Most
studies examining serum pyridinoline were carried out for
longer durations, the average being 16 weeks (26,27). In
these studies, serum pyridinolines in ovariectomized
animals were higher than those in the sham group.
Equivalent results were obtained in studies using urinary
pyridinoline as a marker for bone resorption (28).
Our histomorphometric and biochemical results strongly
indicate that palm tocotrienol was able to prevent the loss
of trabecular bone in accelerated bone loss conditions such
as osteoporosis. An earlier study using palm vitamin E
(which contains a higher percentage of tocotrienols than
tocopherols) showed that this vitamin was effective in
preventing the loss of bone mineral density in osteoporotic
male rats (29). The same study also showed that palm
vitamin E increased the calcium content in rats with
osteoporosis induced by orchidectomy. Similarly, a study
performed by Norazlina et al. (30) showed that vitamin E
deficiency impaired bone calcification, whereas supple-
mentation with palm vitamin E improved the bone calcium
content in growing rats.
The role of antioxidants in scavenging reactive oxygen
species during oxidative stress is well established.
Tocotrienol is a powerful antioxidant from the vitamin E
family. This family consists of eight naturally occurring
isoforms including a-, b-, c- and d-tocopherols as well as a-,
b-, c- and d-tocotrienols. Significant attention has been
focused on tocopherol, most likely because of its abundance.
Tocotrienols are similar to tocopherols except that they
possess three trans double bonds in the hydrocarbon tail
instead of a saturated phytyl tail (31). This unique structure
makes tocotrienol a more potent antioxidant compared with
tocopherol.
Recent scientific studies have shown that tocotrienol is
better able to scavenge free radicals compared with
tocopherol (32-34), most likely because the unsaturated side
chain of tocotrienol penetrates tissues more efficiently,
allowing it to be better distributed in the fatty layers of
the cell membrane (35). Other beneficial effects of tocotrie-
nols such as their anti-cancer, neuroprotective and choles-
terol-lowering properties, have also been reported (36-38).
We did not measure free radicals or antioxidant status in
this experiment, although other studies have shown that
ovariectomy caused an increase in reactive oxygen species
and a decrease in the levels of thiol antioxidants, whereas
administration of 17-beta-estradiol reversed these effects
and prevented bone loss (6,39). We did, however, conduct a
study to measure the level of thiobarbituric acid-reactive
substances (TBARSs), which is an index of lipid peroxida-
tion, and the levels of the antioxidant enzymes glutathione
peroxidase and superoxide dismutase in the femurs of
normal male rats (40). It was shown that rats supplemented
with tocotrienol had a lower TBARS level; however, the
Figure 3 - IL-6 levels in the different groups of rats. * Indicates a
significant difference compared with the ovariectomy (Ovx)
group (p,0.05). Ovx+PTT=Ovariectomy+pure tocotrienol. The
data are presented as the mean¡SEM.
Figure 4 - Osteocalcin levels in the different groups of rats. * Indicates a significant difference compared with the ovariectomy (Ovx)
group (p,0.05). Ovx+PTT=Ovariectomy+pure tocotrienol. The data are presented as the mean¡SEM.
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glutathione peroxidase activity was increased. This finding
indicates that tocotrienol directly enhances the antioxidant
defense system in bone. Another study also showed that
supplementation with tocotrienol more successfully pre-
vented bone loss in rats exposed to nicotine compared with
tocopherol (41). Therefore, modern treatments for osteo-
porosis should be directed toward increasing the bone
antioxidant defense, and tocotrienol should be considered in
the choice of therapy.
In conclusion, treatment with tocotrienol at a dose of
60 mg/kg body weight prevented bone loss due to estrogen
deficiency. Tocotrienol can be potentially used to prevent
postmenopausal osteoporosis in women, provided that
sufficient clinical studies are carried out to establish the
efficacy and safety of this form of antioxidant vitamin.
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